Shineco Announces New Distribution Agreements for over $30 Million in Sales for its New Health Food Beverage
10 Luglio 2024 - 3:00PM
Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a
provider of innovative diagnostic medical products and related
medical devices, announced today that its subsidiary, Fuzhou Meida
Health Management Co., Ltd. (“Fuzhou Meida”), has entered into
Distribution Agreements (the “Agreements”) for its water-soluble
phospholipid concentrate health food beverage with a projected goal
of more than $30 million in sales with six distribution companies,
for a term of three years.
Mrs. Jennifer Zhan, CEO of Shineco, said, “The
Company’s sustained research and development efforts have developed
a production process that is expected to open up a potentially vast
new market for our health food beverage. We believe that our
technologically advanced production process provides a competitive
advantage in the marketplace since it achieves a pure physical
separation and extraction of the naturally active
phospholipids.”
“We have commenced mass production of
phospholipids that addresses the current shortage of supply to meet
the expected higher demand for this health food beverage, and we
are intent upon expanding the market for this uniquely healthy
product. Our strategic plan is to develop products and services in
the healthcare and medical sectors that will generate a diversified
revenue stream with the goal of maximizing shareholder returns,”
CEO Ms. Zhan concluded.
Phospholipids are organic compounds which are
utilized in numerous ways in food and other industries. Further,
phospholipids are a key component of cell membranes, forming a
bilayer that acts as a barrier that allows some molecules to pass
through while blocking others. Phospholipids have important health
effects and are an important element in cell growth and other
physiological processes.
The Company has developed and patented a
technologically advanced process utilizing pure physical extraction
technology for this highly important organic material. Its water
solvent large column chromatography ultrafiltration membrane
protects the natural structure and activity of phospholipids, as no
chemical solvent is involved in the process. Through precise
parameter design and regulation, the Company’s ultrafiltration
membrane structure process restores the natural bilayer of
phospholipid molecules and achieves a precise separation and
extraction of phospholipid molecules. This patented technologically
advanced process results in extraction efficiency, minimizing costs
and maximizing yield.
Shineco plans to continue to research and
develop the application of the naturally active water-soluble
phospholipids in the medical, food, beauty and other fields.
According to the market research firm www.factmr.com, the global
phospholipids market was valued at $3.7 billion in 2021, and with a
projected CAGR of 7.3% over ten years, this market is likely to
reach a valuation of $7.3 billion by the end of 2032.
Shineco also plans to continue to develop new
high value-added products to meet the changing needs of the
healthcare and medical sectors. In addition, it intends to optimize
its global sales network to develop and expand the overseas markets
for its products. Through continuous innovation and the development
of high-quality products, the Company expects to foster a brighter
and healthier future for people around the globe.
About Shineco, Inc.
Shineco Inc. (“Shineco” or the “Company”) aims
to ‘care for a healthy life and improve the quality of life’, by
providing safe, efficient and high-quality health and medical
products and services to society. Shineco, operating through
subsidiaries, has researched and developed 33 vitro diagnostic
reagents and related medical devices to date, and the Company also
produces and sells healthy and nutritious foods. For more
information about Shineco, please visit www.biosisi.com/.
Forward-Looking Statements
This news release contains “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. These forward-looking statements can be
identified by terminology such as “may”, “will”, “should”, “could”,
“intend”, “expect”, “plan”, “budget”, “forecast”, “anticipate”,
“believe”, “estimate”, “predict”, “potential”, “continue”,
“evaluating” or similar words. Forward-looking statements should
not be relied upon because they are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, projections,
anticipated events and trends, the economy and other future
conditions. Examples of forward-looking statements include, among
others, statements we make regarding the innovativeness and market
position of our products and services, our competitive strengths,
and our expectations of product sales by our subsidiaries. You are
cautioned not to rely on any forward-looking statements. Actual
results may differ materially from historical results or those
indicated by the forward-looking statements as a result of a
variety of factors including, but not limited to, risks and
uncertainties associated with the Company’s ability to raise
additional funding, its ability to maintain and grow its business,
variability of operating results, its ability to maintain and
enhance its brand, its development and introduction of new products
and services, the ability to obtain all necessary regulatory
approvals in the jurisdictions where it intends to market and sell
its products the successful integration of acquired companies,
technologies and assets into its portfolio of products and
services, marketing and other business development initiatives,
competition in the industry, general government regulations,
economic conditions, the impact of the COVID-19 pandemic,
dependence on key personnel, the ability to attract, hire and
retain personnel who possess the technical skills and experience
necessary to meet the requirements of its clients, and its ability
to protect its intellectual property. Shineco encourages you to
review other factors that may affect its future results in its
filings with the Securities and Exchange Commission. The
forward-looking statements in this press release are based only on
information currently available to us and speak only as of the date
of this press release, and Shineco assumes no obligation to update
any forward-looking statements except as required by the applicable
rules and regulations.
For more information, please
contact:
Shineco,Inc.secretary@shineco.tech Mobile:
+86-010-68130220
Precept Investor Relations LLCDavid J.
Rudnickdavid.rudnick@preceptir.comMobile: +1-646-694-8538
Grafico Azioni Shineco (NASDAQ:SISI)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Shineco (NASDAQ:SISI)
Storico
Da Gen 2024 a Gen 2025